Caffeic Acid

Caffeic Acid

SCHEMBL21114743

O=C(O)/C=C/c1ccc(O)c(O)c1.O=C(O)C=Cc1ccc(O)c(O)c1.O=C(O)C=Cc1ccc(O)c(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 1.00
HSD17B10 Q99714 3/20 1.00
CA12 O43570 3/20 1.00
CA1 P00915 3/20 1.00
CA2 P00918 3/20 1.00
CA3 P07451 3/20 1.00
CA4 P22748 3/20 1.00
CA6 P23280 3/20 1.00
CA5A P35218 3/20 1.00
CA7 P43166 3/20 1.00
CA9 Q16790 3/20 1.00
CA14 Q9ULX7 3/20 1.00
CA5B Q9Y2D0 3/20 1.00
MAPT P10636 2/20 1.00
TTR P02766 2/20 1.00
APP P05067 2/20 1.00
AKR1B10 O60218 2/20 1.00
AKR1B1 P15121 2/20 1.00
DPP4 P27487 2/20 1.00
MMP1 P03956 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Caffeic Acid SCHEMBL23359 1.00 KDM4E (1.00) KDM4EHSD17B10CA12CA1CA2
Caffeic Acid SCHEMBL30501140 1.00 KDM4E (1.00) KDM4EHSD17B10CA12CA1CA2
Caffeic Acid SCHEMBL29447135 1.00 KDM4E (1.00) KDM4EHSD17B10CA12CA1CA2
Caffeic Acid SCHEMBL30050844 1.00 KDM4E (1.00) KDM4EHSD17B10CA12CA1CA2
Caffeic Acid SCHEMBL29353048 1.00 KDM4E (1.00) KDM4EHSD17B10CA12CA1CA2
Caffeic Acid SCHEMBL3682144 1.00 KDM4E (1.00) KDM4EHSD17B10CA12CA1CA2
Caffeic Acid SCHEMBL7064846 1.00 KDM4E (1.00) KDM4EHSD17B10CA12CA1CA2
Caffeic Acid SCHEMBL23358 1.00 KDM4E (1.00) KDM4EHSD17B10CA12CA1CA2
Caffeic Acid SCHEMBL1262229 1.00 KDM4E (1.00) KDM4EHSD17B10CA12CA1CA2
Caffeic Acid SCHEMBL9477189 0.98 KDM4E (0.96) KDM4EHSD17B10CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11976063-B2 Pharmaceutical composition comprising berberine and ursodeoxycholic acid for the treatment of various diseases or disorders SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD. (CN) 2024-05-07 US disclosed
US-20230348457-A1 BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF SHENZHEN HIGHTIDE BIOPHARMACEUTICAL LTD (CN) 2023-11-02 US disclosed
US-20230295151-A1 BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD. (CN) 2023-09-21 US disclosed
US-11685735-B2 Pharmaceutical composition comprising berberine salts for the treatment of various diseases or disorders SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD. (CN) 2023-06-27 US disclosed
US-10988471-B2 Pharmaceutical composition comprising berberine ursodeoxycholic acid salt for the treatment of various diseases or disorders SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD. (CN) 2021-04-27 US disclosed
EP-3174874-B1 BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF SHENZHEN HIGHTIDE BIOPHARMACEUTICAL LTD (CN) 2020-09-02 EP disclosed
US-20190211007-A1 BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD. (CN) 2019-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348457-A1 BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF CYP27A1, NR1H4, CYP7A1 KDM4E 3717/4885HSD17B10 330/4885CA12 4229/4885
US-20190211007-A1 BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF CYP27A1, NR1H4, CYP7A1 KDM4E 3717/4885HSD17B10 330/4885CA12 4229/4885
US-10988471-B2 Pharmaceutical composition comprising berberine ursodeoxycholic acid salt for the treatment of various diseases or disorders CYP27A1, SLC10A1, NR1H4 KDM4E 3528/4885HSD17B10 265/4885CA12 3939/4885
US-11685735-B2 Pharmaceutical composition comprising berberine salts for the treatment of various diseases or disorders CPT1B, CYP27A1, GLS2 KDM4E 3119/4885HSD17B10 312/4885CA12 4315/4885
US-20230295151-A1 BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF CYP27A1, NR1H4, CYP7A1 KDM4E 3717/4885HSD17B10 330/4885CA12 4229/4885
US-11976063-B2 Pharmaceutical composition comprising berberine and ursodeoxycholic acid for the treatment of various diseases or disorders CYP27A1, NR1H4, CPT1B KDM4E 3553/4885HSD17B10 260/4885CA12 4389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.